Abstract
The acquisition of resistance by extended-spectrum β-lactamases (ESBL) has been reported primarily for Enterobacteriaceae, but there are few reports on the isolation of ESBL-producing Pseudomonas aeruginosa. PER-1-type ESBL producing P. aeruginosa has been found in various regions around the world but there are no reports of clinical isolates in Japan. During our susceptibility surveillance studies over a 10 year period, we found four clinical isolates resistant to ceftazidime due to production of PER-1. They were resistant to ceftazidime but susceptible in the presence of clavulanic acid, a class A β-lactamase inhibitor. The strains had the ability to hydrolyze ceftazidime. They also had the gene for PER-1-type ESBL. This is the first report of the isolation of PER-1 producing strains in Japan. These four strains were resistant to ceftazidime, cefepime and aztreonam with MICs of 64 μg/ml or more, but were more susceptible to carbapenem antibiotics. In particular, doripenem, which is a novel carbapenem antibiotic, showed good antibacterial activity with a MIC of 2 or 4 μg/ml, which was more potent than meropenem and imipenem. Doripenem also showed good therapeutic efficacy against a systemic infection of mice with a PER-1 producing strain, and was also more potent in vivo than imipenem or meropenem.
Similar content being viewed by others
Article PDF
References
Li XZ, Livermore DM, Nikaido H . Role of efflux pumps in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to β-lactam resistance. Antimicrob Agents Chemother 38: 1742–1752 ( 1994)
Jarlier V, Nicolas MH, Fournier G, Phillippon A . Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 10: 867–878 ( 1988)
Weldhagen GF, Poirel L, Nordmann P . Amber class A extended-spectrum β-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother 47: 2385–2392 ( 2003)
Nordmann P, Ronco E, Naas T, Duport C, Michel-Briand Y, Labia R . Characterization of a novel extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 37: 962–969 ( 1993)
Nordmann P, Naas T . Sequence analysis of PER-1 extended-spectrum β-lactamase from Pseudomonas aeruginosa and comparison with class A β-lactamases. Antimicrob Agents Chemother 38: 104–114 ( 1994)
Vahaboglu H, Coskunkan F, Tansel O, Ozturk R, Sahin N, Koksal I, Kocazeybek B, Tatman-Otkun M, Leblebicioglu H, Ozinel MA, Akalin H, Kocagoz S, Korten V . Clinical importance of extended-spectrum β-lactamase (PER-1-type)-producing Acinetobacter spp. and Pseudomonas aeruginosa strains. J Med Microbiol 50: 642–645 ( 2001)
Kolayli F, Gacar G, Karadenizli A, Sanic A, Vahaboglu H . PER-1 is still widespread in Turkish hospitals among Pseudomonas aeruginosa and Acinetobacter spp. FEMS Microbiol Lett 249: 241–245 ( 2005)
Luzzaro F, Mantengoli E, Perilli M, Lombardi G, Orlandi V, Orsatti A, Amicosante G, Rossolini GM, Toniolo A . Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase. J Clin Microbiol 39: 1865–1870 ( 2001)
Claeys G, Verschraegen G, De Baare T, Vaneechoute M . PER-1 β-lactamase-producing Pseudomonas aeruginosa in an intensive care unit. J Antimicrob Chemother 45: 924–925 ( 2000)
De Champs C, Chanal C, Sirot D, Baraduc R, Romaszko JP, Bonnet R, Plaidy A, Boyer M, Carroy E, Gbadamassi MC, Laluque S, Oules O, Poupart MC, Villemain M, Sirot J . Frequency and diversity of class A extended-spectrum β-lactamase in hospital of the Auvergne, France: a 2 year prospective study. J Antimicrob Chemother 54: 634–639 ( 2004)
Pagani L, Mantengoli E, Migliavacca R, Nucleo E, Pollini S, Spalla M, Daturi R, Romero E, Rossolini GM . Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase in Northern Italy. J Clin Microbiol 42: 2523–2529 ( 2004)
Docquier JD, Luzzaro F, Amicosante G, Toniolo A, Rossolini GM . Multidrug-resistant Pseudomonas aeruginosa producing PER-1 extended-spectrum serine-β-lactamase and VIM-2 metallo-β-lactamase. Emerg Infect Dis 7: 910–911 ( 2001)
Iso Y, Irie T, Iwaki T, Kii M, Sendo Y, Motokawa K, Nishitani Y . Synthesis and modification of a novel 1-β-methyl carbapenem antibiotic, S-4661. J Antibiot 49: 478–484 ( 1996)
Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K . In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother 42: 94–99 ( 1998)
Fujimura T, Kimura Y, Yoshida I, Higashiyama I, Jinushi Y, Munekage T, Kuroda N, Doi M, Nishikawa T, Yamano Y . In vitro antibacterial activity of doripenem, a novel parenteral carbapenem. Jpn J Chemother 53 ( S-1): 57–70 ( 2005)
Miwa H, Kimura Y, Jinushi Y, Fujimura T, Nishikawa T, Munekage T, Kuroda N, Yamano Y, Tsuji M, Okazaki K, Sato T, Matsuda H . Antipseudomonal activity of doripenem, a novel parenteral carbapenem. Jpn J Chemother 53 ( S-1): 80–91 ( 2005)
Ge Y, Wikler MA, Sahm DF, Blosser-Middleton RS, Karlowsky JA . In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 48: 1384–1396 ( 2004)
Mushtaq S, Ge Y, Livermore DM . Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob Agents Chemother 84: 1313–1319 ( 2004)
National Committee for Clinical Laboratory Standards (NCCLS): Performance standards for antimicrobial susceptibility testing. Twelfth Informational Supplement M100-S12. Wayne, PA: NCCLS, 2002
Jason JAT . A direct spectrometric assay for penicillin β-lactamase (penicillinase). Biochim Biophys Acta 99: 171–172 ( 1965)
O'Callghan CH, Morris A, Kirby SM, Singler AH . Novel method for detection of β-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother 1: 283–288 ( 1972)
Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA . Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 39: 185–201 ( 2000)
Sato T, Tsuji M, Okazaki K, Matsuda H, Yoshitomi T, Miwa H . Therapeutic efficacy of doripenem, a novel parenteral carbapenem antibiotic, against experimental infection in mice and rats. Jpn J Chemother 53 ( S-1): 71–79 ( 2005)
Sasaki S, Nagano K, Kimura Y, Jinushi Y, Nagata H, Uotani K, Higashiyama H . Surveillance of the susceptibility of clinical isolates of various bacterial species to antibacterial agents. Jpn J Chemother 43: 12–26 ( 1995)
Nagano K, Kimura Y, Higashiyama I, Jinushi Y, Sasaki S, Yoshida I . Surveillance of susceptibility of clinical isolates of various bacterial species to antibacterial agents: No. 2. against gram-negative bacteria in 1994. Jpn J Chemother 44: 610–625 ( 1996)
Yoshida I, Nagano K, Kimura Y, Higashiyama I, Sasaki S . Surveillance of susceptibility of clinical isolates of various bacterial species to antibacterial agents: No. 2. against gram-negative bacteria isolated in 1996. Jpn J Chemother 46: 343–362 ( 1998)
Yoshida I, Higashiyama I, Kimura Y, Sasaki S . Surveillance of susceptibility of clinical isolates of various bacterial species to antibacterial agents: No. 2. gram-negative bacteria isolated in 1998. Jpn J Chemother 48: 610–632 ( 2000)
Yoshida I, Sugimori G, Higashiyama I, Kimura Y, Yamano Y . Surveillance of susceptibility of clinical isolates of various bacterial species to antibacterial agents: antimicrobial activity against gram-negative bacteria isolated in 2000. Jpn J Chemother 51: 209–232 ( 2003)
Yoshida I, Fujimura T, Jinushi Y, Higashiyama I, Kimura Y, Sugimori G, Yamano Y . Surveillance of susceptibility of clinical isolates to antibacterial agents: antibacterial activity against aerobic gram-negative bacteria isolated in 2002. Jpn J Chemother, in press
Yong D, Shin JH, Kim S, Lim Y, Yum JH, Lee K, Chong Y, Bauernfeind Y . High prevalence of PER-1 extended-spectrum β-lactamase-producing Acinetobacter spp. In Korea. Antimicrob Agents Chemother 47: 1749–1751 ( 2003)
Aktas Z, Poirel L, Salcioglu M, Ozcan PE, Midilli K, Bal C, Ang O, Nordmann P . PER-1 and OXA-10-like β-lactamases in ceftazidime-resistant Pseudomonas aeruginosa isolates from intensive care unit patients in Istanbul, Turkey. Clin Microbiol Infect 11: 193–198 ( 2005)
Mushtaq S, Ge Y, Livermore DM . Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 48: 3086–3092 ( 2004)
Yamano Y, Kawai Y, Yutsudo T . Stability of doripenem against human renal dehydropeptidase-I. Jpn J Chemother 53 ( S-1): 92–95 ( 2005)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yamano, Y., Nishikawa, T., Fujimura, T. et al. Occurrence of PER-1 Producing Clinical Isolates of Pseudomonas aeruginosa in Japan and their Susceptibility to Doripenem. J Antibiot 59, 791–796 (2006). https://doi.org/10.1038/ja.2006.104
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ja.2006.104